{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "11053803",
  "DateCompleted": {
    "Year": "2000",
    "Month": "12",
    "Day": "20"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "09",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0924-8579",
      "JournalIssue": {
        "Volume": "16",
        "Issue": "2",
        "PubDate": {
          "Year": "2000",
          "Month": "Oct"
        }
      },
      "Title": "International journal of antimicrobial agents",
      "ISOAbbreviation": "Int J Antimicrob Agents"
    },
    "ArticleTitle": "Out-patient management of febrile neutropenia.",
    "Pagination": {
      "StartPage": "169",
      "EndPage": "171",
      "MedlinePgn": "169-71"
    },
    "Abstract": {
      "AbstractText": [
        "Fever and neutropenia commonly complicated cytotoxic cancer therapy. Although standard therapy is empirical in-patient broad-spectrum intravenous antibiotic therapy until fever and neutropenia resolve, different treatments based on patient risk have been reported over the last decade. The data identifying low risk patients, treatment strategies for low risk patients, and additional information required before recommending out-patient management of fever and neutropenia widely are described."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. jtalcott@partners.org"
          }
        ],
        "LastName": "Talcott",
        "ForeName": "J A",
        "Initials": "JA"
      }
    ],
    "GrantList": [
      {
        "GrantID": "CA 71125",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, U.S. Gov't, P.H.S.",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Netherlands",
    "MedlineTA": "Int J Antimicrob Agents",
    "NlmUniqueID": "9111860",
    "ISSNLinking": "0924-8579"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Bacterial Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Ambulatory Care"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Bacterial Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Clinical Trials as Topic"
    },
    {
      "QualifierName": [
        "complications",
        "drug therapy"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "complications",
        "drug therapy"
      ],
      "DescriptorName": "Neutropenia"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Factors"
    }
  ],
  "NumberOfReferences": "10"
}